Exploring trends in benzodiazepine-positive fatal drug overdoses in Tennessee, 2019–2021

References

• Centers for Disease Control and Prevention [Internet]. Understanding the opioid overdose epidemic. 2022 [cited 2023 Jun 6]. Available from: https://www.cdc.gov/opioids/basics/epidemic.html.
   Google Scholar
• Agarwal S, Landon B. Patterns in outpatient benzodiazepine prescribing in the United States. JAMA Netw Open. 2019;2(1):1. doi: 10.1001/jamanetworkopen.2018.7399.
   Web of Science ®Google Scholar
• Champion C, Kameg B. Best practices in benzodiazepine prescribing and management in primary care. Nurse Pract. 2021;46(3):30–12. doi: 10.1097/01.NPR.0000733684.24949.19.
   PubMed Web of Science ®Google Scholar
• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Benzodiazepines. [Updated 2017 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548298/.
   Google Scholar
• Peppin J, Raffa R, Schatman M. The polysubstance overdose-death crisis. J Pain Res. 2020;13:3405–3408. doi: 10.2147/JPR.S295715.
   PubMed Web of Science ®Google Scholar
• Zawilska J, Wojcieszak J. An expanding world of new psychoactive substances-designer benzodiazepines. Neurotoxicology. 2019;73:8–16. doi: 10.1016/j.neuro.2019.02.015.
   PubMed Web of Science ®Google Scholar
• Orsolini L, Corkery JM, Chiappini S, et al. New/designer benzodiazepines’: an analysis of the literature and psychonauts’ trip reports. Curr Neuropharmacol. 2020;18(9):809–837. doi: 10.2174/1570159X18666200110121333.
   PubMed Web of Science ®Google Scholar
• Carpenter J, Murray B, Dunkley C, et al. Designer benzodiazepines: a report of exposures recorded in the national poison data system, 2014-2017. Clin Toxicol. 2019;57(4):282–286. doi: 10.1080/15563650.2018.1510502.
   PubMed Web of Science ®Google Scholar
• Liu S, O’Donnell J, Gladden RM, et al. Trends in nonfatal and fatal overdoses involving benzodiazepines - 38 states and the District of Columbia, 2019-2020. MMWR Morb Mortal Wkly Rep. 2021;70(34):1136–1141. doi: 10.15585/mmwr.mm7034a2.
   PubMed Web of Science ®Google Scholar
• United Nations Office on Drugs and Crime Early Warning Advisory on New Psychoactive Substances. [Internet]. https://www.unodc.org/LSS/Page/NPS.
   Google Scholar
• Shafi A, Berry A, Sumnall H, et al. New psychoactive substances: a review and updates. Ther Adv Psychopharmacol. 2020;10:2045125320967197. doi: 10.1177/2045125320967197.
   Web of Science ®Google Scholar
• Bollinger K, Weimer B, Heller D, et al. Benzodiazepines reported in NFLIS-Drug, 2015 to 2018. Forensic Sci Int Synerg. 2021;3:100138. doi: 10.1016/j.fsisyn.2021.100138.
   PubMedGoogle Scholar
• Runnstrom M, Kalra S, Lascano J, et al. Overdose from designer benzodiazepine diclazepam. QJM. 2020;113(2):122–124. doi: 10.1093/qjmed/hcz247.
   PubMed Web of Science ®Google Scholar
• Soussan C, Andersson M, Kjellgren A. The diverse reasons for using novel psychoactive substances - A qualitative study of the users’ own perspectives. Int J Drug Policy. 2018;52:71–78. doi: 10.1016/j.drugpo.2017.11.003.
   PubMed Web of Science ®Google Scholar
• Laing M, Ti L, Marmel A, et al. An outbreak of novel psychoactive substance benzodiazepines in the unregulated drug supply: preliminary results from a community drug checking program using point-of-care and confirmatory methods. Int J Drug Policy. 2021;93:103169. doi: 10.1016/j.drugpo.2021.103169.
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction [Internet]. European drug report 2020: trends and developments. 2020 [cited 2023 Nov 7]. Available from: European Drug Report 2020: Trends and Developments | www.emcdda.europa.eu
   Google Scholar
• Bachhuber M, Hennessy S, Cunningham C, et al. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013. Am J Public Health. 2016;106(4):686–688. doi: 10.2105/AJPH.2016.30306.
   PubMed Web of Science ®Google Scholar
• Horigian V, Schmidt R, Feaster D. Loneliness, mental health, and substance use among US young adults during COVID-19. J Psychoactive Drugs. 2021;53(1):1–9. doi: 10.1080/02791072.2020.1836435.
   PubMed Web of Science ®Google Scholar
• Stack E, Leichtling G, Larsen J, et al. The impacts of COVID-19 on mental health, substance use, and overdose concerns of people who use drugs in rural communities. J Addict Med. 2021;15(5):383–389. doi: 10.1097/ADM.0000000000000770.
   PubMed Web of Science ®Google Scholar
• Van Baelen L, Gremeaux L, Antoine J, et al. COVID-19 and people who use drugs: impact of the pandemic on general anxiety and depressive disorders among adults in Belgium. J Affect Disord. 2021;295:946–953. doi: 10.1016/j.jad.2021.08.069.
   PubMed Web of Science ®Google Scholar
• Williams L, Lee E, Latkin C, et al. Economic challenges and behavioral and mental health risks for overdose during the COVID-19 pandemic among people who inject drugs. Int J Environ Res Public Health. 2022;19(9):195351. doi: 10.3390/ijerph19095351.
   Web of Science ®Google Scholar
• Tennessee Department of Health. Office of Informatics and Analytics. [Internet]. Tennessee state unintentional drug overdose reporting system (SUDORS) report 2023. 2023 [cited 2023 Jul 1]. Available from: https://www.tn.gov/content/dam/tn/health/documents/pdo/sudors/SUDORS_Annual_Report_2023.pdf.
   Google Scholar
• Harris P, Taylor R, Minor B, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:95103208. doi: 10.1016/j.jbi.2019.103208.
   Web of Science ®Google Scholar
• Harris P, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi: 10.1016/j.jbi.2008.08.010.
   PubMed Web of Science ®Google Scholar
• Korona-Bailey J, Nechuta S, Golladay M, et al. Characteristics of fatal opioid overdoses with stimulant involvement in Tennessee: a descriptive study using 2018 state unintentional drug overdose reporting system data. Ann Epidemiol. 2021;58:149–155. doi: 10.1016/j.annepidem.2021.03.004.
   PubMed Web of Science ®Google Scholar
• Roberts A, Saint S. Enhancing SUDORS in Tennessee: using web forms and automation to improve data quality, reduce errors, and save time. Overdose Data to Action Recipient Meeting; 2021, June 22-23. Virtual.
   Google Scholar
• Ingram D, Franco S. 2013 NCHS urban-rural classification scheme for counties. [internet. Vital Health Stat 2. 2014;166(166):1–73. Available at: https://www.cdc.gov/nchs/data/series/sr_02/sr02_166.pdf
   Google Scholar
• Centers for Disease Control and Prevention National Center for Health Statistics. [Internet]. Single-race population estimates, United States July 1st resident population by state, county, age, sex, single-race, and Hispanic origin, on CDC WONDER Online Database. 2022 [cited 2023 Jul 1]. Available at: https://wonder.cdc.gov/.
   Google Scholar
• Manchester K, Lomas E, Waters L, et al. The emergence of new psychoactive substance (NPS) benzodiazepines: a review. Drug Test Anal. 2018;2018;10(2):392–393. doi: 10.1002/dta.2349.
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Administration (DEA). [Internet]. Emerging threat report annual 2020 [cited 2023 Jul 1]. Available from: DEA-Emerging-Threat-Report-2020-Annual.pdf (umd.edu)
   Google Scholar
• Park T, Saitz R, Ganoczy D, et al. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015;350:h2698. doi: 10.1136/bmj.h2698.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration (FDA). [Internet]. FDA drug safety communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. September 20, 2017 [cited 2023 Jul 1]. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or.
   Google Scholar
• Conway F, Samora J, Brinkley K, et al. Impact of COVID-19 among people who use drugs: a qualitative study with harm reduction workers and people who use drugs. Harm Reduct J. 2022;19(1):72. doi: 10.1186/s12954-022-00653-1.
   PubMed Web of Science ®Google Scholar
• Frueh L, Collins A, Newman R, et al. Multi-level influences on increased overdose risk behaviors during the COVID-19 pandemic among people who use drugs in Rhode Island: a qualitative investigation. Harm Reduct J. 2023;20(1):14. doi: 10.1186/s12954-023-00741-w.
   PubMed Web of Science ®Google Scholar
• Del Rio A, Graziano S, Tittarelli R, et al. Increasing diversion of prescribed benzodiazepines and Z-drugs to new psychoactive substances. Clin Ter. 2021;172(2):116–118. doi: 10.7417/CT.2021.2296.
   PubMedGoogle Scholar
• Greenblatt H, Greenblatt D. Designer benzodiazepines: a review of published data and public health significance. Clin Pharmacol Drug Dev. 2019;8(3):266–269. doi: 10.1002/cpdd.667.
   PubMed Web of Science ®Google Scholar
• Winstock A, Davies E, Gilchrist G, et al. [Internet]. Global drug survey special edition on COVID-19 global interim report. Global Drug Survey. February 6, 2020 [cited 2023 Jul 1]. Available at: https://www.globaldrugsurvey.com/wp-content/themes/globaldrugsurvey/assets/GDS_COVID-19-GLOBAL_Interim_Report-2020.pdf.
   Google Scholar
• Sarangi A, McMahon T, Gude J. Benzodiazepine misuse: an epidemic within a pandemic. Cureus. 2021;13(6):13e15816. doi: 10.7759/cureus.15816.
   Web of Science ®Google Scholar
• United Nations Office on Drugs and Crime (UNODC). [Internet]. World drug report 2022. Booklet 2 – global overview of drug demand and drug supply. 2022 [cited 2023 Jul 1]. Available at: https://www.unodc.org/res/wdr2022/MS/WDR22_Booklet_2.pdf.
   Google Scholar
• Maust D, Lin L, Blow F. Benzodiazepine use and misuse among adults in the United States. Psychiatr Serv. 2019;70(2):97–106. doi: 10.1176/appi.ps.201800321.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration (SAMHSA). [Internet]. Center for behavioral health statistics and quality. racial/ethnic differences in substance use, substance use disorders, and substance use treatment utilization among people aged 12 or older (2015-2019). 2021 [cited 2023 Jun 1]. Available at: https://www.samhsa.gov/data/report/racialethnic-differences-substance-use.
   Google Scholar
• Cook B, Creedon T, Wang Y, et al. Examining racial/ethnic differences in patterns of benzodiazepine prescription and misuse. Drug Alcohol Depend. 2018;187:29–34. doi: 10.1016/j.drugalcdep.2018.02.011.
   PubMed Web of Science ®Google Scholar
• Ribas Roca J, Everett T, Dongarwar D, et al. Racial-ethnic disparities in benzodiazepine prescriptions for anxiety in US emergency departments. J Racial Ethn Health Disparities. 2023;10(1):334–342. doi: 10.1007/s40615-021-01224-z.
   PubMed Web of Science ®Google Scholar
• Kariisa M, Davis N, Kumar S, et al. Vital signs: drug overdose deaths, by selected sociodemographic and social determinants of health characteristics - 25 states and the District of Columbia, 2019-2020. MMWR Morb Mortal Wkly Rep. 2022;71(29):940–947. doi: 10.15585/mmwr.mm7129e2.
   PubMed Web of Science ®Google Scholar
• Gainsbury S. Cultural competence in the treatment of addictions: theory, practice and evidence. Clin Psychol Psychother. 2017;24(4):987–1001. doi: 10.1002/cpp.2062.
   PubMed Web of Science ®Google Scholar
• Tannenbaum C, Martin P, Tamblyn R, et al. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890–898. doi: 10.1001/jamainternmed.2014.949.
   PubMed Web of Science ®Google Scholar
• Krotulski A. [Internet]. Challenges in identifying novel psychoactive substances and a stronger path forward. National Institute of Justice. 2022 [cited 2023 Jun 6]. Available at: https://nij.ojp.gov/topics/articles/challenges-identifying-novel-psychoactive-substances-and-stronger-path-forward.
   Google Scholar
• Krotulski A, Varnum S, Logan B. Sample mining and data mining: combined real-time and retrospective approaches for the identification of emerging novel psychoactive substances. J Forensic Sci. 2020;65(2):550–562. doi: 10.1111/1556-4029.14184.
   PubMed Web of Science ®Google Scholar
• Hondebrink L, Nugteren-van Lonkhuyzen J, Van Der Gouwe D, et al. Monitoring new psychoactive substances (NPS) in The Netherlands: data from the drug market and the poisons information centre. Drug Alcohol Depend. 2015;147:109–115. doi: 10.1016/j.drugalcdep.2014.11.033.
   PubMed Web of Science ®Google Scholar
• Brunt T, Nagy C, Bücheli A, et al. Drug testing in Europe: monitoring results of the trans European drug information (TEDI) project. Drug Test Anal. 2017;9(2):188–198. doi: 10.1002/dta.1954.
   PubMed Web of Science ®Google Scholar
• McCrae K, Tobias S, Tupper K, et al. Drug checking services at music festivals and events in a Canadian setting. Drug Alcohol Depend. 2019;205:107589. doi: 10.1016/j.drugalcdep.2019.107589.
   PubMed Web of Science ®Google Scholar
• Public Chapter No. 764, T.N. Annotated Code § 39-17-402(12)(8). 2022 [cited 2023 Jun 7]. Available at: https://legiscan.com/TN/text/HB2177/2021.
   Google Scholar
• Tennessee Department of Health. [Internet]. Harm reduction and syringe services programs (SSPs). [cited 2023 Jun 7]. Available at: https://www.tn.gov/health/health-program-areas/std/std/syringe-services-program.html.
   Google Scholar
• Virginia Department of Health. [Internet]. Comprehensive harm reduction and syringe services program. [cited 2023 Jun 7]. Available at: https://www.vdh.virginia.gov/lenowisco/harm-reduction/.
   Google Scholar